{'fraction_non_alphanumeric': 0.01828681424446583, 'fraction_numerical': 0.014436958614051972, 'mean_word_length': 5.046511627906977, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mutations in the BAP1 gene in uveal melanoma

Purpose Uveal melanoma (UM) is the most frequently occurring intraocular malignancy in adults. UM has a strong tendency to metastasize to the liver. There are no effective therapies for metastatic disease resulting in a tumour‐related death in about 45% of UM patients within 15 years after the initial diagnosis. Monosomy of chromosome 3 is the most frequent found chromosomal aberration in UM and is predominantly found in metastasizing tumours. Chromosome 3 losses can be detected by karyotyping, FISH or DNA based techniques as QPCR/MLPA and Array CGH. We use a combination of FISH and SNP arrays to select patients for a dendritic cell therapy trial. Recently, inactivating somatic mutations were identified in the gene encoding BRCA1‐associated protein 1 (BAP1) on chromosome 3p21.1 in metastasizing tumours. In a retrospective series of UMs we will determine the sensitivity and specificity of mutations in BAP1 and compare these with the currently used predictive standard of monosomy.